Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FPQOM
ADC Name
XMT-1660
Synonyms
XMT 1660; XMT-1660; XMT1660
   Click to Show/Hide
Organization
Mersana Therapeutics, Inc.
Drug Status
Phase 1
Indication
In total 6 Indication(s)
Breast cancer
Phase 1
Clinical Trial
Endometrial cancer
Phase 1
Clinical Trial
Fallopian tube cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Peritoneal cancer
Phase 1
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
6
Structure
Antibody Name
Emiltatug
  Antibody Info 
Antigen Name
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
  Antigen Info 
Payload Name
Dolasynthen
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Cleavable ester linker
  Linker Info 
Conjugate Type
Reactive Cysteines
Combination Type
ledadotin